Business Context and Reporting Period
This Form 8-K was filed by electroCore, Inc. on September 25, 2019. The company is incorporated in Delaware and trades on the NASDAQ Global Select Stock Market under the symbol ECOR. The filing reports a specific event regarding the company's regulatory progress rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory update and does not contain financial statement data.
Material Changes
There are no material financial changes reported in this document. The primary event is the issuance of a press release on September 25, 2019, providing an update on the company's 510(k) submission to the FDA for the use of its gammaCore device in migraine prevention.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) regarding the 510(k) submission status. No specific financial guidance, management commentary on future performance, or detailed risk factors are included in the text of this 8-K. The document identifies the company as an emerging growth company.
Investor Verification Checklist
- Review the full text of the press release filed as Exhibit 99.1 for specific details on the 510(k) submission status.
- Verify the current regulatory timeline for gammaCore migraine prevention approval.
- Check subsequent filings for any financial impact resulting from this regulatory update.
- Confirm the company's emerging growth company status and its implications for financial reporting standards.